Simcha launches with $25M WuXi-led series A, new take on IL-18 for cancer
With IP from a Yale lab, Simcha hopes its IL-18 variant will circumvent a resistance mechanism in tumors
Simcha emerged Wednesday with $25 million in series A funding to bring its lead product, a variant of IL-18 designed to thwart a resistance mechanism in tumors, through Phase I testing.
The corporate venture fund of WuXi AppTec Co. Ltd. (Shanghai:603259; HKEX:2359) led Simcha Therapeutics’ financing, which closed in May. Other investors included Sequoia Capital China and Connecticut Innovations. WuXi’s Lennart Lee and Sequoia’s Trency Gu serve on Simcha’s board...